Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Smoked cannabis may be an effective treatment for spasticity

A clinical study of 30 adult patients with multiple sclerosis (MS) at the University of California, San Diego School of Medicine has shown that smoked cannabis may be an effective treatment for spasticity - a common and disabling symptom of this neurological disease.

15 May 2012

FDA clears Bioness smaller leg cuff for use with L300 Foot Drop System

Bioness Inc. today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market a smaller leg cuff for use with the company's L300 Foot Drop System.

14 May 2012

FDA warns about 'liberation therapy' for multiple sclerosis

The U.S. Food and Drug Administration is alerting health care professionals and patients about injuries and death associated with the use of an experimental procedure sometimes called "liberation therapy" or the "liberation procedure" to treat chronic cerebrospinal venous insufficiency (CCSVI).

11 May 2012

Glial cells pass on metabolites to neurons

Around 100 billion neurons in the human brain enable us to think, feel and act. They transmit electrical impulses to remote parts of the brain and body via long nerve fibres known as axons. This communication requires enormous amounts of energy, which the neurons are thought to generate from sugar. Axons are closely associated with glial cells which, on the one hand, surround them with an electrically insulating myelin sheath and, on the other hand support their long-term function.

11 May 2012

Misdiagnosis of MS more common than previously thought

It is relatively common for doctors to diagnose someone with multiple sclerosis when the patient doesn't have the disease - a misdiagnosis that not only causes patients potential harm but costs the U.S. health care system untold millions of dollars a year, according to a study published online today in the journal Neurology.

10 May 2012

EU and U.S. regulatory authorities accept Biogen Idec’s BG-12 NDA for review

Today Biogen Idec announced that U.S. and EU regulatory authorities have accepted the company's marketing applications for the review of BG-12 (dimethyl fumarate), an oral therapeutic candidate for the treatment of multiple sclerosis.

10 May 2012

Grade 12 researcher wins top honors at 2012 Sanofi BioGENEius Challenge Canada

An Ontario girl, 16, who invented a disease-fighting, anti-aging compound using nano-particles from trees, won top national honours today in the 2012 Sanofi BioGENEius Challenge Canada.

9 May 2012

AARDA's Autoimmune Walk campaign surpasses first $20,000 fundraising milestone

Just a month after announcing its first-ever national "Autoimmune Walk: Linking Together for a Cure" campaign, American Autoimmune Related Diseases Association (AARDA) announced today that it has surpassed its first $20,000 fundraising milestone.

9 May 2012

Teva first quarter net revenues increase 25% to $5.1 billion

Teva Pharmaceutical Industries Ltd. today reported results for the quarter ended March 31, 2012.

9 May 2012

Accentia, Johns Hopkins co-host meeting with prospective clinical trial investigators at AAN meeting

Accentia Biopharmaceuticals, Inc. today announced that the Company and leading physicians from Johns Hopkins University co-hosted a meeting with prospective clinical trial investigators at the recent American Academy of Neurology (AAN) Annual Meeting in New Orleans.

7 May 2012

Kessler Foundation scientists to share new findings at international multiple sclerosis congress

Kessler Foundation will be represented by four scientists at the inaugural International Congress on Cognition in Multiple Sclerosis to be held at the Congress Center in Bordeaux, France on May 11 & 12, 2012.

3 May 2012

Foods rich in omega-3 fatty acids linked with lower blood beta-amyloid levels

A new study suggests that eating foods that contain omega-3 fatty acids, such as fish, chicken, salad dressing and nuts, may be associated with lower blood levels of a protein related to Alzheimer's disease and memory problems.

3 May 2012

XenoPort first quarter revenues increase to $10.4 million

XenoPort, Inc. announced today its financial results for the first quarter ended March 31, 2012. Revenues for the quarter were $10.4 million, compared to $0.4 million for the same period in 2011.

3 May 2012

Enrollment complete in Hanger’s WalkAide System clinical trial for stroke

Hanger Orthopedic Group, Inc. today announced the completion of enrollment in its pivotal INSTRIDE investigational device exemption (IDE) clinical trial studying the effectiveness of its WalkAide System in the rehabilitation of stroke survivors.

3 May 2012

Biogen Idec first quarter revenues increase 7% to $1.3 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies, today announced its first quarter 2012 results.

2 May 2012

Antibody that neutralizes enzyme Kallikrein 6 staves off MS

Researchers studying multiple sclerosis(MS) have long been looking for the specific molecules in the body that cause lesions in myelin, the fatty, insulating cells that sheathe the nerves.

30 Apr 2012

Kadimastem, Merck Serono enter agreement for MS drug-screening platform

Kadimastem, an Israeli Biotechnology company that develops human pluripotent stem cell-related products, today announced the signing of a five year framework agreement with Merck Serono, a division of Merck KGaA, Darmstadt, Germany.

30 Apr 2012

Researchers define structure of key part of human obesity receptor

Medical researchers at the University of Sheffield have defined the structure of a key part of the human obesity receptor- an essential factor in the regulation of body fat- which could help provide new treatments for the complications of obesity and anorexia.

27 Apr 2012

Rochester researcher to continue MS study

A Rochester, New York, researcher will receive a $263,622 grant to continue his study of injury to brain cell connections (synapses) in multiple sclerosis (MS) through the American Brain Foundation (formerly the American Academy of Neurology Foundation) and the National Multiple Sclerosis Society Clinician-Scientist Development Award.

27 Apr 2012

HMS researcher receives $130,000 to conduct epilepsy study

A researcher from Beth Israel Deaconess Medical Center and Harvard Medical School is receiving $130,000 to conduct further research on memory dysfunction in epilepsy patients through the Susan S. Spencer Clinical Research Training Fellowship.

27 Apr 2012